search icon
  • What's New in Practice Management & Payment

    CMS: Fact Sheet for the QPP Year 2 Proposed Rule

    AMA Releases New MIPS Resources

    CMS Releases Lookup Tool to Help Clinicians Determine their MIPS Participation Status

    CMS: New Quality Payment Program Resources Available

    MIPS 2017: Important Dates & Information

  • Upcoming Meetings

    IDWeek 2017 logo
    30 July - 4 August, 2017 | Vail, Colorado

    35th Annual Conference on Pediatric Infectious Diseases

    August 10 - 13, 2017 | Stanford, CA

    7th International Coccidioidomycosis Symposium

    August 26 - 30, 2017 | Tysons Corner, VA

    2017 Infectious Disease Board Review Course

  • Policy News


    IDSA urges Congress to continue U.S. leadership in confronting infectious diseases

    In written testimony submitted to United States Senate Appropriations State and Foreign Operations Subcommittee prior to its June 13 review of the FY2018 White House budget proposal, IDSA President Dr. Bill Powderly urged Senators to sustain robust funding for global infectious disease security and responses. The testimony is here.

  • Breaking News and Alerts

    5/22/2017 2:17:49 PM

    Ongoing Transmission of Candida auris in Health Care Facilities

    CDC has just released an MMWR update on Candida auris (C. auris) cases identified in U.S. health care facilities through May 2017.

    5/18/2017 1:29:25 PM

    Potential for Falsely Low Blood Lead Test Results from LeadCare® Analyzers

    The U.S. Food and Drug Administration (FDA) has issued a safety communication warning about the use of Magellan Diagnostics’ LeadCare® analyzers (LeadCare, LeadCare II, LeadCare Ultra and LeadCare Plus) with venous blood samples because they might result in falsely low test results. FDA is now advising that Magellan Diagnostics’ LeadCare® analyzers should no longer be used with venous blood samples. The safety alert does not apply to capillary blood lead test results collected by fingerstick or heelstick. The purpose of this Health Advisory is to notify state and local health departments, healthcare providers, and laboratories about CDC’s re-testing guidance in light of the safety alert.

    6/12/2017 1:00:29 PM

    Prolonged IgM Antibody Response in People Infected with Zika Virus: Implications for Interpreting Serologic Testing Results for Pregnant Women

    In July 2016, CDC issued Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure – United States, July 2016 ( that includes Zika virus immunoglobulin M (IgM) testing of pregnant women.

    5/4/2017 10:03:31 AM

    U.S.-licensed yellow fever vaccine supply to be depleted by mid-2017

    The Centers for Disease Control and Prevention outlines a plan to ensure a continuous yellow fever vaccine supply in the United States following the anticipated depletion of the U.S.-licensed YF-VAX® yellow fever vaccine in mid-2017, according to a Morbidity and Mortality Weekly Report published April 28, 2017.

    4/10/2017 12:24:52 PM

    FDA approves two hepatitis C drugs for pediatric patients

    The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults.

    4/4/2017 3:21:04 PM

    CDC: About 1 in 10 U.S. pregnant women with confirmed Zika infection had a fetus or baby with birth defects in 2016

    Of the 250 pregnant women who had confirmed Zika infection in 2016, 24 – or about 1 in 10 of them – had a fetus or baby with Zika-related birth defects, according to a new Vital Signs report from the Centers for Disease Control and Prevention (CDC). This report is the first to provide the analysis of a subgroup of pregnant women in the U.S. with clear, confirmed test results of Zika virus infection.

    3/27/2017 12:24:20 PM

    CDC Updates Specimen Collection, Shipping, and Testing Guidance for Suspected Acute Flaccid Myelitis (AFM) Cases

    Despite extensive pathogen-specific testing of many specimens since 2014, CDC and others have not identified an etiology for the AFM cases. Therefore, CDC will no longer perform clinical diagnostics for enteroviruses or metagenomic sequencing on specimens collected from suspect cases of AFM.

    3/27/2017 12:10:57 PM

    Information for Healthcare Personnel Potentially Exposed to Hepatitis C Virus (HCV): Recommended Testing and Follow-up

    Exposure to viral hepatitis has long been recognized as an occupational risk for healthcare personnel, with recommendations previously established for the management of occupational exposures to hepatitis C virus (HCV). 

  • News from IDSA and the Journals

    IDSA, AASLD Express Concerns About Cochrane Review of DAAs for Hep C


    We are writing to express our serious concerns regarding the recent Cochrane Group Review concluding that there is a lack of valid evidence supporting the benefit of direct acting antiviral (DAA) therapy for chronic infection with hepatitis C virus (HCV), and its supposition: “the possibility of potentially harming people with chronic hepatitis ought to be considered before treating people with hepatitis C with DAAs.”

| HIVMA | Contact Us

© Copyright IDSA 2017 Infectious Diseases Society of America

Full Site Mobile Site